BACKGROUND: Declining rates of hospitalizations occurred shortly after the availability of highly active antiretroviral therapy (HAART). However, trends in the late HAART era are less defined, and data on the impact of CD4 counts and HAART use on hospitalizations are needed. METHODS: We evaluated hospitalization rates from 1999 to 2007 among HIV-infected persons enrolled in a large US military cohort. Poisson regression was used to compare hospitalization rates per year and to examine factors associated with hospitalization. RESULTS: Of the 2429 participants, 822 (34%) were hospitalized at least once with 1770 separate hospital admissions. The rate of hospitalizations (137 per 1000 person-years) was constant over the study period [relative rate (RR) 1.00 per year change, 95% confidence interval: 0.98 to 1.02]. The hospitalization rates due to skin infections (RR: 1.50, P = 0.02), methicillin-resistant staphylococcus aureus (RR: 3.19, P = 0.03), liver disease (RR: 1.71, P = 0.04), and surgery (RR: 1.17, P = 0.04) significantly increased over time, whereas psychological causes (RR: 0.60, P < 0.01) and trauma (RR: 0.54, P < 0.01) decreased. In the multivariate model, higher nadir CD4 (RR: 0.92 per 50 cells, P < 0.01) and higher proximal CD4 counts (RR of 0.71 for 350-499 vs. <350 cells/mm(3) and RR 0.67 for > or = 500 vs. 350 cells/mm(3), both P < 0.01) were associated with lower risk of hospitalization. Risk of hospitalization was constant for proximal CD4 levels above 350 (RR: 0.94 P = 0.51, CD4 > or = 500 vs. 350-499). HAART was associated with a reduced risk of hospitalization among those with a CD4 <350 (RR: 0.72, P = 0.02) but had smaller estimated and nonsignificant effects at higher CD4 levels (RR: 0.81, P = 0.33 and 1.06, P = 0.71 for CD4 350-499 and > or = 500, respectively). CONCLUSIONS: Hospitalizations continue to occur at high rates among HIV-infected persons with increasing rates for skin infections, methicillin-resistant staphylococcus aureus, liver disease, and surgeries. Factors associated with a reduced risk of hospitalization include CD4 counts >350 cells per cubic millimeter and HAART use among patients with a CD4 count <350 cells per cubic millimeter.
BACKGROUND: Declining rates of hospitalizations occurred shortly after the availability of highly active antiretroviral therapy (HAART). However, trends in the late HAART era are less defined, and data on the impact of CD4 counts and HAART use on hospitalizations are needed. METHODS: We evaluated hospitalization rates from 1999 to 2007 among HIV-infected persons enrolled in a large US military cohort. Poisson regression was used to compare hospitalization rates per year and to examine factors associated with hospitalization. RESULTS: Of the 2429 participants, 822 (34%) were hospitalized at least once with 1770 separate hospital admissions. The rate of hospitalizations (137 per 1000 person-years) was constant over the study period [relative rate (RR) 1.00 per year change, 95% confidence interval: 0.98 to 1.02]. The hospitalization rates due to skin infections (RR: 1.50, P = 0.02), methicillin-resistant staphylococcus aureus (RR: 3.19, P = 0.03), liver disease (RR: 1.71, P = 0.04), and surgery (RR: 1.17, P = 0.04) significantly increased over time, whereas psychological causes (RR: 0.60, P < 0.01) and trauma (RR: 0.54, P < 0.01) decreased. In the multivariate model, higher nadir CD4 (RR: 0.92 per 50 cells, P < 0.01) and higher proximal CD4 counts (RR of 0.71 for 350-499 vs. <350 cells/mm(3) and RR 0.67 for > or = 500 vs. 350 cells/mm(3), both P < 0.01) were associated with lower risk of hospitalization. Risk of hospitalization was constant for proximal CD4 levels above 350 (RR: 0.94 P = 0.51, CD4 > or = 500 vs. 350-499). HAART was associated with a reduced risk of hospitalization among those with a CD4 <350 (RR: 0.72, P = 0.02) but had smaller estimated and nonsignificant effects at higher CD4 levels (RR: 0.81, P = 0.33 and 1.06, P = 0.71 for CD4 350-499 and > or = 500, respectively). CONCLUSIONS: Hospitalizations continue to occur at high rates among HIV-infected persons with increasing rates for skin infections, methicillin-resistant staphylococcus aureus, liver disease, and surgeries. Factors associated with a reduced risk of hospitalization include CD4 counts >350 cells per cubic millimeter and HAART use among patients with a CD4 count <350 cells per cubic millimeter.
Authors: Nancy Crum-Cianflone; Katherine Huppler Hullsiek; Vincent Marconi; Amy Weintrob; Anuradha Ganesan; R Vincent Barthel; Susan Fraser; Brian K Agan; Scott Wegner Journal: AIDS Date: 2009-01-02 Impact factor: 4.177
Authors: José del Valle; Juan Macías; José Antonio Mira; José Angel García-García; Jesús Gómez-Mateos; Juan Antonio Pineda Journal: Enferm Infecc Microbiol Clin Date: 2008-10 Impact factor: 1.731
Authors: E J Beck; S Mandalia; I Williams; A Power; R Newson; A Molesworth; D Barlow; P Easterbrook; M Fisher; J Innes; G Kinghorn; B Mandel; A Pozniak; A Tang; D Tomlinson Journal: AIDS Date: 1999-10-22 Impact factor: 4.177
Authors: Simon Paul; Holly M Gilbert; Leah Lande; Carlos M Vaamonde; Jonathan Jacobs; Sharp Malak; Kent A Sepkowitz Journal: AIDS Res Hum Retroviruses Date: 2002-05-01 Impact factor: 2.205
Authors: L Martín-Carbonero; V Soriano; E Valencia; J García-Samaniego; M López; J González-Lahoz Journal: AIDS Res Hum Retroviruses Date: 2001-11-01 Impact factor: 2.205
Authors: Yu-Hsiang Hsieh; Richard E Rothman; John G Bartlett; Samual Yang; Gabor D Kelen Journal: J Acquir Immune Defic Syndr Date: 2008-12-01 Impact factor: 3.731
Authors: Carla Núñez-Fernández; Luz Martín-Carbonero; Maria Eulalia Valencia; Juan Aguilera; Javier García-Samaniego; Juan Gonzalez-Lahoz; Vicente Soriano Journal: AIDS Res Hum Retroviruses Date: 2009-04 Impact factor: 2.205
Authors: Ank E Nijhawan; Ellen Kitchell; Sarah Shelby Etherton; Piper Duarte; Ethan A Halm; Mamta K Jain Journal: AIDS Patient Care STDS Date: 2015-07-08 Impact factor: 5.078
Authors: Lisa R Metsch; Daniel J Feaster; Lauren Gooden; Tim Matheson; Maxine Stitzer; Moupali Das; Mamta K Jain; Allan E Rodriguez; Wendy S Armstrong; Gregory M Lucas; Ank E Nijhawan; Mari-Lynn Drainoni; Patricia Herrera; Pamela Vergara-Rodriguez; Jeffrey M Jacobson; Michael J Mugavero; Meg Sullivan; Eric S Daar; Deborah K McMahon; David C Ferris; Robert Lindblad; Paul VanVeldhuisen; Neal Oden; Pedro C Castellón; Susan Tross; Louise F Haynes; Antoine Douaihy; James L Sorensen; David S Metzger; Raul N Mandler; Grant N Colfax; Carlos del Rio Journal: JAMA Date: 2016-07-12 Impact factor: 56.272
Authors: Joyce L Sanchez; Peter W Hunt; Cavan S Reilly; Hiroyu Hatano; Gregory J Beilman; Alexander Khoruts; Jake S Jasurda; Ma Somsouk; Ann Thorkelson; Samuel Russ; Jodi Anderson; Steven G Deeks; Timothy W Schacker Journal: J Infect Dis Date: 2014-10-24 Impact factor: 5.226
Authors: Anna L Hotton; Kathleen M Weber; Ronald C Hershow; Kathryn Anastos; Peter Bacchetti; Elizabeth T Golub; Deborah Gustafson; Alexandra M Levine; Mary Young; Mardge H Cohen Journal: J Acquir Immune Defic Syndr Date: 2017-06-01 Impact factor: 3.731
Authors: Jason E Farley; Matthew J Hayat; Paul L Sacamano; Tracy Ross; Karen Carroll Journal: Am J Infect Control Date: 2015-02-14 Impact factor: 2.918
Authors: Stephen A Berry; John A Fleishman; Baligh R Yehia; P Todd Korthuis; Allison L Agwu; Richard D Moore; Kelly A Gebo Journal: AIDS Date: 2013-08-24 Impact factor: 4.177